The Business Times
business-time-50

Novartis

International

Novartis misses Q1 profit estimates on steep generic erosion

The transaction will strengthen Novartis’ presence in the market of immunology in food allergy.
Companies & Markets

Novartis to buy US-based biotech firm Excellergy for up to US$2 billion

Novartis is introducing a new pill for an autoimmune skin ailment, and to bolster growth, CEO Narasimhan is also clinching deals.
International

Novartis expects profit to decline in 2026 amid competition

Novartis will pay US$55 million upfront to combine its expertise in immuno-dermatology with the British firm’s drug discovery AI platform.
Companies & Markets

Novartis strikes deal with UK biotech for up to US$1.7 billion

The company confirmed its 2025 guidance with sales expected to grow by a “high single-digit” percentage and adjusted operating income to grow by a “low-teens” percentage.
Companies & Markets

Novartis Q3 operating income up 6% on new drug sales

Novartis, which focuses on heart, kidney and metabolic drugs, immunology, neuroscience and oncology, is looking to boost its portfolio.
Consumer & Healthcare

Novartis agrees to buy Avidity in US$12 billion biotech deal

The company's strategy towards becoming carbon neutral involves reducing its energy consumption, and ensuring clean supply solutions from renewable energy sources.
ESG

Novartis Singapore steps up in the race to net zero

The Swiss drugmaker will pay US$48 per share in cash for the New York-based biotech, which is developing a promising treatment to reduce systemic inflammation, a major driver of cardiovascular disease. 
Consumer & Healthcare

Novartis to buy US biotech Tourmaline Bio for US$1.4 billion

Novartis joins a growing number of multinational drug companies to announce investments in the US this year.
Consumer & Healthcare

Novartis pledges US$23 billion US investment as tariffs loom

“With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients,” says Bill Meury, CEO at Anthos.
Consumer & Healthcare

Novartis to acquire Anthos for up to US$3.1 billion

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More